Adenosinergic and dopaminergic interaction in nigrostriatum in FeCl3-induced model of parkinsonism in rats.
The effect of adenosine modulating drugs was studied in the FeCl3-induced model of parkinsonism in rats. In rats bearing unilateral FeCl3 induced lesion of the dopaminergic nigrostriatal pathway, stimulation of adenosine receptors with adenosine, dose-dependently reduced the ipsilateral rotations induced by apomorphine. A specific agonist of adenosine A2A receptor, CGS-21680, also completely blocked the rotations while the specific A2 receptor antagonist, CGS-15943A, potentiated rotations induced by apomorphine. The nonspecific adenosine antagonist, theophylline (50 mg/kg i.p.) potentiated stereotype behavior although blocking rotations. This study provides evidence for a negative postsynaptic interaction between dopamine and adenosine receptors.
Mathur
R
R
Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India.
Gupta
Y K
YK
D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000502:physiology*; D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology; D001058:Apomorphine / Q000494:pharmacology; D002712:Chlorides; D004195:Disease Models, Animal; D004298:Dopamine / Q000502:physiology*; D005260:Female; D005290:Ferric Compounds / Q000633:toxicity*; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D010627:Phenethylamines / Q000494:pharmacology; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D011799:Quinazolines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D018047:Receptors, Purinergic P1 / Q000502:physiology; D013239:Stereotyped Behavior / Q000187:drug effects; D013378:Substantia Nigra / Q000187:drug effects*; D014230:Triazoles / Q000494:pharmacology
D000978:Antiparkinson Agents; D002712:Chlorides; D005290:Ferric Compounds; D010627:Phenethylamines; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D011799:Quinazolines; D018047:Receptors, Purinergic P1; D014230:Triazoles; C061282:2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine; D000241:Adenosine; D001058:Apomorphine; C024555:ferric chloride; D004298:Dopamine; C052410:9-chloro-2-(2-furyl)-(1,2,4)triazolo(1,5-c)quinazolin-5-imine